Cargando…
The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186332/ https://www.ncbi.nlm.nih.gov/pubmed/35759239 http://dx.doi.org/10.1002/iid3.664 |
_version_ | 1784724909214138368 |
---|---|
author | Ma, Tao Ding, Songning Huang, Rui Wang, Hengxue Wang, Junjun Liu, Jiacheng Wang, Jian Li, Jie Wu, Chao Fan, Huafeng Zhou, Nan |
author_facet | Ma, Tao Ding, Songning Huang, Rui Wang, Hengxue Wang, Junjun Liu, Jiacheng Wang, Jian Li, Jie Wu, Chao Fan, Huafeng Zhou, Nan |
author_sort | Ma, Tao |
collection | PubMed |
description | INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. METHODS: The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. RESULTS: Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). CONCLUSIONS: The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era. |
format | Online Article Text |
id | pubmed-9186332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91863322022-06-14 The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era Ma, Tao Ding, Songning Huang, Rui Wang, Hengxue Wang, Junjun Liu, Jiacheng Wang, Jian Li, Jie Wu, Chao Fan, Huafeng Zhou, Nan Immun Inflamm Dis Short Reports INTRODUCTION: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have resulted in new challenges for epidemic prevention and control worldwide. However, little is known about the latent period of coronavirus disease by the SARS‐CoV‐2 Delta variant of concern (VOC) in the postvaccination era. METHODS: The epidemiology and clinical data of cases with confirmed SARS‐CoV‐2 Delta VOC infection were retrospective collected. Dates of the first positive PCR test were collected to estimate the distribution of latent period. RESULTS: Of the 40 patients, 16 were male (40%). The median age of patients was 47.5 years. The median latent period of patients was 6.0 days (interquartile range [IQR], 4.0−9.0 days) and the longest latent period was 13.0 days after exposure. The latent periods were longer in male patients compared to female patients (median, 8.5 days vs. 5.0 days, p = .041). The median latent period was comparable among fully vaccinated cases (6.5 days), no vaccinated cases (7.5 days), and partially vaccinated cases (5.5 days). CONCLUSIONS: The median latent period of SARS‐CoV‐2 Delta VOC infection was 6.0 days. The latent period between vaccinated and non‐vaccinated patients was not significantly different. The 14‐day quarantine program is sufficient to prevent the transmission of COVID‐19 by Delta VOC in the postvaccination era. John Wiley and Sons Inc. 2022-06-10 /pmc/articles/PMC9186332/ /pubmed/35759239 http://dx.doi.org/10.1002/iid3.664 Text en © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Reports Ma, Tao Ding, Songning Huang, Rui Wang, Hengxue Wang, Junjun Liu, Jiacheng Wang, Jian Li, Jie Wu, Chao Fan, Huafeng Zhou, Nan The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title_full | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title_fullStr | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title_full_unstemmed | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title_short | The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era |
title_sort | latent period of coronavirus disease 2019 with sars‐cov‐2 b.1.617.2 delta variant of concern in the postvaccination era |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186332/ https://www.ncbi.nlm.nih.gov/pubmed/35759239 http://dx.doi.org/10.1002/iid3.664 |
work_keys_str_mv | AT matao thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT dingsongning thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT huangrui thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wanghengxue thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wangjunjun thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT liujiacheng thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wangjian thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT lijie thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wuchao thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT fanhuafeng thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT zhounan thelatentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT matao latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT dingsongning latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT huangrui latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wanghengxue latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wangjunjun latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT liujiacheng latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wangjian latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT lijie latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT wuchao latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT fanhuafeng latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera AT zhounan latentperiodofcoronavirusdisease2019withsarscov2b16172deltavariantofconcerninthepostvaccinationera |